-
1
-
-
34447522035
-
In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate
-
DOI 10.1160/TH07-03-0183
-
Wienen W, Stassen JM, Priepke H, et al. In vitro profile and ex vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007; 98: 155-62. (Pubitemid 47078782)
-
(2007)
Thrombosis and Haemostasis
, vol.98
, Issue.1
, pp. 155-162
-
-
Wienen, W.1
Stassen, J.-M.2
Priepke, H.3
Ries, U.J.4
Hauel, N.5
-
2
-
-
26444498631
-
The role of P-glycoprotein and organic anion-transporting polypeptides in drug interactions
-
DOI 10.2165/00002018-200528090-00004
-
DuBuske LM. The role of P-glycoprotein and organic anion-transporting polypeptides in drug interactions. Drug Saf 2005; 28: 789-801. (Pubitemid 41428552)
-
(2005)
Drug Safety
, vol.28
, Issue.9
, pp. 789-801
-
-
DuBuske, L.M.1
-
3
-
-
41949116970
-
Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate
-
DOI 10.2165/00003088-200847050-00001
-
Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47: 285-95. (Pubitemid 351508116)
-
(2008)
Clinical Pharmacokinetics
, vol.47
, Issue.5
, pp. 285-295
-
-
Stangier, J.1
-
4
-
-
33645779998
-
Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects
-
Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006; 46: 549-58.
-
(2006)
J Clin Pharmacol
, vol.46
, pp. 549-558
-
-
Kubitza, D.1
Becka, M.2
Zuehlsdorf, M.3
Mueck, W.4
-
5
-
-
58149401862
-
Apixaban, an oral direct Factor Xa inhibitor: Awaiting the verdict
-
Carreiro J, Ansell J. Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict Expert Opin Investig Drugs 2008; 17: 1937-45.
-
(2008)
Expert Opin Investig Drugs
, vol.17
, pp. 1937-1945
-
-
Carreiro, J.1
Ansell, J.2
-
6
-
-
77952044405
-
Assessment of laboratory assays to measure rivaroxaban: An oral, direct factor Xa inhibitor
-
Samama MM, Martinou JL, LeFlem L, et al. Assessment of laboratory assays to measure rivaroxaban: an oral, direct factor Xa inhibitor. Thromb Haemost 2011; 103: 815-25.
-
(2011)
Thromb Haemost
, vol.103
, pp. 815-825
-
-
Samama, M.M.1
Martinou, J.L.2
LeFlem, L.3
-
7
-
-
33750023407
-
Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: A population model analysis
-
DOI 10.1111/j.1365-2125.2006.02667.x
-
Liesenfeld KH, Schäfer HG, Trocóniz IF, et al. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol 2006; 62: 527-37. (Pubitemid 44571573)
-
(2006)
British Journal of Clinical Pharmacology
, vol.62
, Issue.5
, pp. 527-537
-
-
Liesenfeld, K.-H.1
Schafer, H.G.2
Troconiz, I.F.3
Tillmann, C.4
Eriksson, B.I.5
Stangier, J.6
-
8
-
-
35449007749
-
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: The RE-MODEL randomized trial
-
DOI 10.1111/j.1538-7836.2007.02748.x
-
Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5: 2178-85. (Pubitemid 47617868)
-
(2007)
Journal of Thrombosis and Haemostasis
, vol.5
, Issue.11
, pp. 2178-2185
-
-
Eriksson, B.I.1
Dahl, O.E.2
Rosencher, N.3
Kurth, A.A.4
Van Dijk, C.N.5
Frostick, S.P.6
Kalebo, P.7
Christiansen, A.V.8
Hantel, S.9
Hettiarachchi, R.10
Schnee, J.11
Buller, H.R.12
-
9
-
-
34548575058
-
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double-blind, non-inferiority trial
-
DOI 10.1016/S0140-6736(07)61445-7, PII S0140673607614457
-
Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, noninferiority trial. Lancet 2007; 370: 949-56. (Pubitemid 47393577)
-
(2007)
Lancet
, vol.370
, Issue.9591
, pp. 949-956
-
-
Eriksson, B.I.1
Dahl, O.E.2
Rosencher, N.3
Kurth, A.A.4
Van Dijk, C.N.5
Frostick, S.P.6
Prins, M.H.7
Hettiarachchi, R.8
Hantel, S.9
Schnee, J.10
Buller, H.R.11
-
10
-
-
57649123692
-
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery
-
RE-MOBILIZE Writing Committee
-
RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009; 24: 1-9.
-
(2009)
J Arthroplasty
, vol.24
, pp. 1-9
-
-
Ginsberg, J.S.1
Davidson, B.L.2
-
11
-
-
33847094672
-
Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery
-
Trocóniz IF, Tillmann C, Liesenfeld KH, et al. Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery, j Clin Pharmacol 2007; 47: 371-82.
-
(2007)
J Clin Pharmacol
, vol.47
, pp. 371-382
-
-
Trocóniz, I.F.1
Tillmann, C.2
Liesenfeld, K.H.3
-
12
-
-
77953791161
-
Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: A pooled analysis of three trials
-
Friedman RJ, Dahl OE, Rosencher N, et al. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res 2010; 126: 175-82.
-
(2010)
Thromb Res
, vol.126
, pp. 175-182
-
-
Friedman, R.J.1
Dahl, O.E.2
Rosencher, N.3
-
13
-
-
45949099359
-
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty
-
DOI 10.1056/NEJMoa0800374
-
Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-75. (Pubitemid 351930851)
-
(2008)
New England Journal of Medicine
, vol.358
, Issue.26
, pp. 2765-2775
-
-
Eriksson, B.I.1
Borris, L.C.2
Friedman, R.J.3
Haas, S.4
Huisman, M.V.5
Kakkar, A.K.6
Bandel, T.J.7
Beckmann, H.8
Muehlhofer, E.9
Misselwitz, F.10
Geerts, W.11
-
14
-
-
46049106502
-
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double-blind, randomised controlled trial
-
Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372: 31-9.
-
(2008)
Lancet
, vol.372
, pp. 31-39
-
-
Kakkar, A.K.1
Brenner, B.2
Dahl, O.E.3
-
15
-
-
45949103416
-
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty
-
DOI 10.1056/NEJMoa076016
-
Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-86. (Pubitemid 351930852)
-
(2008)
New England Journal of Medicine
, vol.358
, Issue.26
, pp. 2776-2786
-
-
Lassen, M.R.1
Ageno, W.2
Borris, L.C.3
Lieberman, J.R.4
Rosencher, N.5
Bandel, T.J.6
Misselwitz, F.7
Turpie, A.G.G.8
-
16
-
-
65549169515
-
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): A randomised trial
-
Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial, Lancet 2009; 373: 1673-80.
-
(2009)
Lancet
, vol.373
, pp. 1673-1680
-
-
Turpie, A.G.1
Lassen, M.R.2
Davidson, B.L.3
-
17
-
-
69749090257
-
Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: Rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery
-
Van Thiel D, Kalodiki E, Wahi R, et al. Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery. Clin Appl Thromb Hemost 2009; 15: 389-94.
-
(2009)
Clin Appl Thromb Hemost
, vol.15
, pp. 389-394
-
-
Van Thiel, D.1
Kalodiki, E.2
Wahi, R.3
-
18
-
-
77649113258
-
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): A randomised double-blind trial
-
Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375: 807-15.
-
(2010)
Lancet
, vol.375
, pp. 807-815
-
-
Lassen, M.R.1
Raskob, G.E.2
Gallus, A.3
-
19
-
-
64349107688
-
Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran
-
Ezekowitz MD, Connolly S, Parekh A, et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran, Am Heart J 2009; 157: 805-10- 810 e1-2.
-
(2009)
Am Heart J
, vol.157
-
-
Ezekowitz, M.D.1
Connolly, S.2
Parekh, A.3
-
20
-
-
70349306707
-
Dabigatran versus warfarin in patients with atrial fibrillation
-
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
-
(2009)
N Engl J Med
, vol.361
, pp. 1139-1151
-
-
Connolly, S.J.1
Ezekowitz, M.D.2
Yusuf, S.3
-
21
-
-
85058721877
-
Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: Rationale and design of the ROCKET AF study
-
ROCKET AF Study Investigators.
-
ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study. Am Heart) 2010; 159: 340-7.
-
(2010)
Am Heart
, vol.159
, pp. 340-347
-
-
-
22
-
-
77649249878
-
Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: Design and rationale
-
Lopes RD, Alexander JH, Al-Khatib SM, et al. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010; 159: 331-9.
-
(2010)
Am Heart J
, vol.159
, pp. 331-339
-
-
Lopes, R.D.1
Alexander, J.H.2
Al-Khatib, S.M.3
-
23
-
-
77649254746
-
Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment
-
Eikelboom JW, O'Donnell M, Yusuf S, et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment Am Heart J 2010; 159: 348-53.
-
(2010)
Am Heart J
, vol.159
, pp. 348-353
-
-
Eikelboom, J.W.1
O'Donnell, M.2
Yusuf, S.3
-
24
-
-
71849117615
-
Dabigatran versus warfarin in the treatment of acute venous thromboembolism
-
Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-52.
-
(2009)
N Engl J Med
, vol.361
, pp. 2342-2352
-
-
Schulman, S.1
Kearon, C.2
Kakkar, A.K.3
-
25
-
-
77951277384
-
Once-daily oral rivaroxaban versus placebo in the long-term prevention of recurrent symptomatic venous thromboembolism. The Einstein-extension study
-
Buller HR. Once-daily oral rivaroxaban versus placebo in the long-term prevention of recurrent symptomatic venous thromboembolism. The Einstein-extension study. ASH Annual Meeting Abstracts 2009; 114: LBA-2.
-
(2009)
ASH Annual Meeting Abstracts
, vol.114
-
-
Buller, H.R.1
|